Prescription Drug Affordability Board

Reserve the date: January 27, 2025

Upcoming Meeting: Prescription Drug Affordability Board, January 27, 2025 at 2:00 PM. More information can be found here. This meeting will be virtual.
The Board invites public comment concerning Farxiga and Jardiance in connection with the cost review study. Under COMAR 14.01.04.05D, the Board may consider oral public comment made at the Board meeting, and written comments. Please visit the 2025 Board Meetings page, under the January 27, 2025 meeting (Cost Review Study Process) to learn more.

NOTICE OF PROPOSED ACTION:

The Maryland Prescription Drug Affordability Board proposes to:

(1) Amend Regulation .01 under COMAR 14.01.01 General Provisions;

(2) Adopt new Regulation .06 under COMAR 14.01.01 General Provisions;

(3) Adopt new Regulations .01—.09 under a new chapter, COMAR 14.01.05 Policy Review, Final Action, Upper Payment Limits.

The text of the proposed amendments and regulations are available in the January 10, 2025 edition of the Maryland Register located here.

Comments may be sent to:

Christina Shaklee, Health Policy Analyst Advanced

Maryland Prescription Drug Affordability Board

16900 Science Drive, Suite 112-114

Bowie, MD 20715;

or call 410-703-7015;

or email to christina.shaklee1@maryland.gov

Comments will be accepted through February 10, 2025.